A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.

Guinn, Barbara-Ann; Schuler, Patrick J; Schrezenmeier, Hubert; Hofmann, Susanne; Weiss, Johanna; Bulach, Christiane; Götz, Marlies; Greiner, Jochen

Guinn, Barbara-Ann; Schuler, Patrick J; Schrezenmeier, Hubert; Hofmann, Susanne; Weiss, Johanna; Bulach, Christiane; Götz, Marlies; Greiner, Jochen.

Afiliação

Guinn BA; Centre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.
Schuler PJ; Department of Otorhinolaryngology, University Hospital Ulm, 89081 Ulm, Germany.
Schrezenmeier H; Institute of Transfusion Medicine, University of Ulm and German Red Cross, 89073 Ulm, Germany.
Hofmann S; Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Weiss J; Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.
Bulach C; Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.
Götz M; Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.
Greiner J; Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany.

Int J Mol Sci ; 24(11)2023 May 26.

Article em En | MEDLINE | ID: mdl-37298237

Assuntos

Leucemia Mieloide Aguda; Linfócitos T; Humanos; Lenalidomida/farmacologia; Lenalidomida/uso terapêutico; Nivolumabe/farmacologia; Nivolumabe/uso terapêutico; Leucemia Mieloide Aguda/patologia; Imunoterapia; Imunidade

Palavras-chave

acute myeloid leukemia; anti-programmed death 1 (PD-1); immunotherapy; lenalidomide; leukemia-associated antigens

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfócitos T / Leucemia Mieloide Aguda Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google